Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04624178 · ClinicalTrials.gov registry record · Phase 2
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
A Phase 2 study of Leiomyosarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 7
- Study locations
NCT04624178 is a Phase 2 study of Leiomyosarcoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants, below the 121-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (83% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT04624178, a Phase 2 study of Leiomyosarcoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out whether combining the study drugs rucaparib and nivolumab may be an effective treatment for advanced and/or metastatic LMS, and whether the study treatment works as well as the standard chemotherapy for this type of cancer.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Rucaparib
Study Locations (7)
New York
- Memorial Sloan Kettering Commack (Limited protocol activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-11-05 |
| Est. Completion | 2026-11-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04624178
The ClinicalTrials.gov registry entry for NCT04624178 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 121-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (83% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leiomyosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT04624178 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04624178 about?
NCT04624178 is a clinical study titled "A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma". The purpose of this study is to find out whether combining the study drugs rucaparib and nivolumab may be an effective treatment for advanced and/or metastatic LMS, and whether the study treatment works as well as the standard chemotherapy for this type of cancer.
What is the current status of trial NCT04624178?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2020-11-05. Estimated completion is 2026-11-16.
What conditions does trial NCT04624178 study?
This clinical trial studies the following conditions: Leiomyosarcoma.
What interventions are being tested in trial NCT04624178?
The interventions under investigation include: Nivolumab (DRUG), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT04624178?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04624178 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
RECRUITING · Phase 2
-
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Nivolumab in Selected Uterine Cancer Patients
COMPLETED · Phase 2
-
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
COMPLETED · Phase 2
-
Bevacizumab and Radiation Therapy for Sarcomas
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.